enVVeno Medical Corp NVNO
Medical/Dental Instruments · IPO 2018 · data as of November 13, 2026
enVVeno Medical Corp (NVNO) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -43%.
About enVVeno Medical
enVVeno Medical is listed in the US and classified in medical/dental instruments, IPO year 2018. It was profitable in 0 of the last 9 years in our data. Its share count rose by 83% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $31243 | $186552 | $422111 |
| Net income | -$19M | -$22M | -$24M | -$25M | -$17M | -$9M | -$8M | -$13M | -$8M |
| Free cash flow | -$16M | -$17M | -$19M | -$16M | -$12M | -$8M | -$6M | -$6M | -$4M |
| EPS (diluted) | $-33.06 | $-44.53 | $-66.82 | $-76.96 | $-66.47 | $-263.78 | $-423.30 | $-1530.54 | $-1180.70 |
| Net margin | — | — | — | — | — | — | -24406.7% | -6991.5% | -1845.8% |
| ROIC | -59.3% | -43.5% | -41.9% | -48.7% | -23.7% | -90.5% | -328.4% | -304.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does enVVeno Medical pay a dividend?
Not currently.
Is enVVeno Medical a good stock to buy?
We do not give buy or sell advice. enVVeno Medical scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.